Kameda H

ORCID: 0000-0002-4330-5782 · 1 paper in corpus
2020
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy ·doi:10.1007/s40259-019-00403-z

ObjectiveOur objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout…